HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J Appl Physiol 102: 374-381, 2007. First published October 26, 2006; doi:10.1152/japplphysiol.00901.2006
8750-7587/07 $8.00

This Article Free upon publication Full Text Free Full Text (PDF) Free All Versions of this Article: 102/1/374    most recent 00901.2006v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Battram, D. S. Articles by Graham, T. E. Search for Related Content PubMed PubMed Citation Articles by Battram, D. S. Articles by Graham, T. E.

Acute caffeine ingestion does not impair glucose tolerance in persons with tetraplegia

¹Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario; and ²Hamilton Health Sciences, Chedoke Site, Hamilton, Ontario, Canada

Submitted 16 August 2006 ; accepted in final form 13 October 2006

Acute caffeine (Caf) ingestion impairs glucose tolerance in able-bodied humans during an oral glucose tolerance test (OGTT). The mechanism responsible for this effect remains unclear, however, it is suggested to be due to the accompanying increase in epinephrine concentration. We examined whether or not Caf would elicit a glucose intolerance in persons with tetraplegia (TP) who do not exhibit an increased epinephrine response following Caf ingestion. All TP [n = 14; 9 incomplete (Inc) lesion, 5 complete (Com) lesion] completed two OGTT 1 h after consuming either gelatin (Pl) or Caf capsules (dose = 4 mg/kg). Blood samples were collected at baseline (time = 0 min), 1 h after capsule ingestion (time = 60 min), and every 30 min during the OGTT (time = 90–180 min). Glucose, insulin, proinsulin, and C-peptide responses were similar (P > 0.05) between treatments, demonstrating no effect of Caf on glucose tolerance. This lack of a Caf effect may be due to the low epinephrine concentration that remained unchanged (P > 0.05) throughout all experiments. Interestingly, the Com exhibited a 50% higher glucose response (P 0.05) and a 46% (P > 0.05) lower insulin response (vs. Inc), suggesting a more pronounced glucose intolerance within this subgroup. Furthermore, nine TP (5 Com, 4 Inc) had glucose levels of 7.8 mM at the end of the OGTT (time = 180 min), classifying them as glucose intolerant. In summary, acute Caf ingestion does not increase epinephrine concentration or impair glucose tolerance in TP.

adenosine receptor antagonist; Type 2 diabetes; spinal cord injury; insulin resistance

This article has been cited by other articles:

				D. S. Battram, T. E. Graham, and F. Dela Caffeine's impairment of insulin-mediated glucose disposal cannot be solely attributed to adrenaline in humans J. Physiol., September 15, 2007; 583(3): 1069 - 1077. [Abstract] [Full Text] [PDF]